Tag: PFE

Pfizer’s Revenue Challenges Pfizer, the pharmaceutical giant, has recently experienced significant setbacks in its revenue due to the decline in its Covid business. The company had to reverse approximately $3.5 billion in revenue, which was expected from the return of 6.5 million doses of its Covid drug, Paxlovid, from the U.S. government. This reversal has […]

Understanding Pfizer’s Projections In its guidance announcement on Wednesday last week, Pfizer detailed its expectations for the year 2024. With the demand for COVID-19-related vaccines and treatments gradually waning, Pfizer anticipated that sales of Comirnaty (the Pfizer coronavirus vaccine) and Paxlovid (the Pfizer treatment for coronavirus) would amount to only approximately $8 billion. Additionally, Pfizer’s […]

Cancer drug Padcev approved Pfizer’s stock experienced a positive surge on Monday in response to the latest approval from the Food and Drug Administration (FDA). The company’s shares closed the day 1.6% higher, surpassing the 0.5% rise of the S&P 500 index. In an announcement made that morning, Pfizer revealed that Padcev, a cancer drug […]

Pfizer’s Business Outlook Securing at least $1 million for retirement is a challenging goal, but investing in stocks, especially early on, can significantly help investors accomplish it. However, not all stocks are equal. Some can drive investors towards their millionaire status, while others may have the opposite effect. Let’s explore whether Pfizer, a prominent drugmaker, […]

Underwhelming Revenue Projections Pfizer has provided its revenue outlook for 2024, expecting a range between $58.5 billion and $61.5 billion. This estimate includes a predicted contribution of approximately $3.1 billion from the company’s pending acquisition of Seagen. Notably, these figures display minimal year-over-year growth for Pfizer, as the projected revenue for 2023 already falls within […]